2026-W46 · Nov 9–Nov 15 · Company · Profile · published
McKesson company profile · pharmaceutical distribution and health services · history · financial snapshot · S&P 500 rank #100 · 麥克森公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | MCK (NYSE) |
| Company | McKesson Corporation |
| GICS sector / industry | Health Care / Health Care Distributors |
| S&P 500 rank (by weight) | #100 · 0.18% (Nov 5, 2026) |
| Sector rank (by S&P 500 weight) | #17 in Health Care (Nov 5, 2026) |
| Headquarters | Irving, Texas |
| Founded | 1833, founded in New York City by Charles M. Olcott and John McKesson |
| CEO | Brian S. Tyler (chairman & CEO) |
| Employees | >43,000 employees, including 1,400 part-time (FY2025 10-K) |
| Market cap | $123.82B (Nov 5, 2026) |
| SEC filings | EDGAR — CIK 0000927653 |
WHAT IT DOES
McKesson Corporation is a diversified health-care services company and the leading pharmaceutical distributor in North America. It distributes branded, generic and specialty pharmaceuticals and other health-care products, and provides related services in procurement, inventory management and logistics. Commencing in the second quarter of fiscal 2026, the company reports four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions and Medical-Surgical Solutions, with its former Norwegian operations in Other. McKesson’s fiscal year ends March 31.
Fiscal 2026 revenues were $403.43B, up 12% year on year, and net income attributable to McKesson Corporation was $4.76B, or $38.38 per diluted share (adjusted EPS $39.11), against $3.30B and $25.72 in fiscal 2025. North American Pharmaceutical supplied $336.65B of revenues, Oncology & Multispecialty $48.42B, Prescription Technology Solutions $5.81B and Medical-Surgical Solutions $11.51B. Distribution is a very thin-margin business: segment operating-profit margins in fiscal 2026 were about 1.09% in North American Pharmaceutical against about 17.98% in Prescription Technology Solutions.
The growth mix is shifting toward higher-margin platforms: Oncology & Multispecialty revenues grew about 31% in fiscal 2026, helped by acquisitions and specialty distribution, while the core pharmaceutical distribution business grows with prescription volumes, including GLP-1 products.
SEGMENTS — FY2026 REVENUES
| Segment | Revenues | Share | YoY |
|---|---|---|---|
| North American Pharmaceutical | $336.65B | 83.4% | +10.6% |
| Oncology & Multispecialty | $48.42B | 12.0% | +31.4% |
| Prescription Technology Solutions | $5.81B | 1.4% | +11.3% |
| Medical-Surgical Solutions | $11.51B | 2.9% | +1.1% |
| Other | $1.04B | 0.3% | −4.0% |
HISTORY
| Year | Milestone |
|---|---|
| 1833 | Charles M. Olcott and John McKesson found the business in New York City as a drug importer and wholesaler (Olcott & McKesson). |
| 1967 | McKesson merges with Foremost Dairies to form Foremost-McKesson; the company later refocuses on health care and takes back the McKesson name. |
| 1999 | McKesson merges with HBO & Company (HBOC), combining drug distribution with health-care information technology. |
| 2019 | Brian S. Tyler becomes chief executive officer. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2026 (ENDED MAR 31, 2026)
| Total revenues | $403.43B |
| Net income attributable to McKesson Corporation | $4.76B |
| Diluted EPS | $38.38 |
| Adjusted EPS (non-GAAP) | $39.11 |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
McKesson is the S&P 500’s pharmaceutical-distribution bellwether: its prescription volumes, specialty mix and segment margins read as a gauge of U.S. medicine consumption, drug-price dynamics and health-system demand. At rank #100 by weight (0.18%) — Health Care #17 — it converts the largest revenue line in the index into a thin but highly cash-generative distribution margin.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price, market cap — Nov 5, 2026 crawl, single source) |
| Financials | Form 10-K for fiscal 2026 (year ended Mar 31, 2026), filed May 8, 2026 |
| Sector classification | GICS via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | MCK(NYSE) |
| 公司 | McKesson Corporation |
| GICS 板塊/行業 | 健康護理/Health Care Distributors |
| 標普500排名(按權重) | 第100名 · 0.18%(2026 年 11 月 5 日) |
| 板塊內排名(按標普500權重) | 健康護理第17名(2026 年 11 月 5 日) |
| 總部 | 得克薩斯州歐文 |
| 成立 | 1833年,由 Charles M. Olcott 及 John McKesson 於紐約市創立 |
| 行政總裁 | Brian S. Tyler(主席兼行政總裁) |
| 員工 | 超過43,000名員工,包括1,400名兼職(FY2025 10-K) |
| 市值 | $123.82B(2026 年 11 月 5 日) |
| SEC 文件 | EDGAR — CIK 0000927653 |
業務概覽
麥克森公司是一家多元化健康護理服務公司,亦是北美領先的藥品分銷商。公司分銷品牌藥、仿製藥及專科藥品以及其他健康護理產品,並提供採購、庫存管理及物流等相關服務。自 fiscal 2026 第二季起,公司報告四個板塊:North American Pharmaceutical、Oncology & Multispecialty、Prescription Technology Solutions 及 Medical-Surgical Solutions,其前挪威業務列入其他。麥克森的財政年度於3月31日結束。
Fiscal 2026 收入為4,034.3億美元,同比增長12%;歸屬於麥克森公司的淨利潤為47.6億美元,攤薄每股收益38.38美元(經調整每股收益39.11美元),而 fiscal 2025 為33.0億美元及25.72美元。North American Pharmaceutical 貢獻收入3,366.5億美元,Oncology & Multispecialty 484.2億美元,Prescription Technology Solutions 58.1億美元,Medical-Surgical Solutions 115.1億美元。分銷是利潤極薄的業務:fiscal 2026 板塊營運利潤率在 North American Pharmaceutical 約為1.09%,而 Prescription Technology Solutions 約為17.98%。
增長組合正轉向利潤較高的平台:Oncology & Multispecialty 收入於 fiscal 2026 增長約31%,受惠於收購及專科分銷,而核心藥品分銷業務則隨處方量(包括 GLP-1 產品)增長。
板塊 — FY2026 收入
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| North American Pharmaceutical | 3,366.5億美元 | 83.4% | +10.6% |
| Oncology & Multispecialty | 484.2億美元 | 12.0% | +31.4% |
| Prescription Technology Solutions | 58.1億美元 | 1.4% | +11.3% |
| Medical-Surgical Solutions | 115.1億美元 | 2.9% | +1.1% |
| 其他 | 10.4億美元 | 0.3% | −4.0% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1833年 | Charles M. Olcott 及 John McKesson 於紐約市創立該業務(Olcott & McKesson),從事藥品進口及批發。 |
| 1967年 | 麥克森與 Foremost Dairies 合併,組成 Foremost-McKesson;公司其後重新聚焦健康護理,並恢復 McKesson 名稱。 |
| 1999年 | 麥克森與 HBO & Company(HBOC)合併,將藥品分銷與健康護理資訊科技結合。 |
| 2019年 | Brian S. Tyler 出任行政總裁。 |
競爭地位
財務快照 — FY2026(截至2026年3月31日)
| 總收入 | 4,034.3億美元 |
| 歸屬於麥克森公司的淨利潤 | 47.6億美元 |
| 攤薄每股收益 | 38.38美元 |
| 經調整每股收益(非 GAAP) | 39.11美元 |
主要風險
對標普500的重要性
麥克森是標普500中藥品分銷的風向標:其處方量、專科組合及板塊利潤,可反映美國藥物消費、藥價動態及醫療系統需求。按權重排名第100位(0.18%)——健康護理第17名——它將指數中最大的收入線轉化為微薄但高度產生現金的分銷利潤。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格、市值——2026 年 11 月 5 日抓取,單一來源) |
| 財務 | Fiscal 2026 10-K(截至2026年3月31日的年度),2026年5月8日提交 |
| 板塊分類 | GICS,據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 17:14 · updated 2026-11-14 23:47 · rev 5